Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06096675 · ClinicalTrials.gov registry record · NA
CAPACITY (Cardiac Amyloidosis and Physical ACtivITY) Study
A NA study of Cardiac Amyloidosis, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT06096675 is a NA study of Cardiac Amyloidosis that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 50 participants, below the 948-participant average among 8 other Cardiac Amyloidosis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06096675, a NA study of Cardiac Amyloidosis, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
Exercise training in patients with heart failure and preserved ejection fraction (HFpEF) has been associated with an improvement in cardiorespiratory fitness and quality of life.
Conditions Studied
Interventions
- BEHAVIORAL • Cardiac Rehabilitation
Study Locations (1)
North Carolina
- Sanger Heart and Vascular Institute - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-01-22 |
| Est. Completion | 2027-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06096675
The ClinicalTrials.gov registry entry for NCT06096675 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 948-participant average among 8 other Cardiac Amyloidosis trials with a reported enrollment target (95% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cardiac Amyloidosis appearing as the primary indexed condition, and to 1 intervention - of which • Cardiac Rehabilitation is the first listed.
NCT06096675 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT06096675 about?
NCT06096675 is a clinical study titled "CAPACITY (Cardiac Amyloidosis and Physical ACtivITY) Study". Exercise training in patients with heart failure and preserved ejection fraction (HFpEF) has been associated with an improvement in cardiorespiratory fitness and quality of life.
What is the current status of trial NCT06096675?
This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2024-01-22. Estimated completion is 2027-06.
What conditions does trial NCT06096675 study?
This clinical trial studies the following conditions: Cardiac Amyloidosis.
What interventions are being tested in trial NCT06096675?
The interventions under investigation include: • Cardiac Rehabilitation (BEHAVIORAL).
Who is sponsoring clinical trial NCT06096675?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06096675 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiac Amyloidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cardiovascular Multimodality Imaging Study
RECRUITING
-
Artificial Intelligence Guided Echocardiographic Screening of Rare Diseases (EchoNet-Screening)
RECRUITING
-
Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis
RECRUITING
-
US Benchmarking Clinical Study
RECRUITING
-
Molecular Imaging of Myocardial Fibrosis in Cardiac Amyloidosis
RECRUITING · Phase 3
-
Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.